Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies

EBioMedicine. 2021 May:67:103373. doi: 10.1016/j.ebiom.2021.103373. Epub 2021 May 6.

Authors

Rachel Strykowski¹, Ayodeji Adegunsoye²

Affiliations

¹ Section of Pulmonary & Critical Care, Department of Medicine, The University of Chicago, Chicago, IL, United States. Electronic address: Rachel.Strykowski@uchospitals.edu.
² Section of Pulmonary & Critical Care, Department of Medicine, The University of Chicago, Chicago, IL, United States. Electronic address: deji@uchicago.edu.

No abstract available

Publication types

Comment

MeSH terms

Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Idiopathic Pulmonary Fibrosis* / etiology

Grants and funding

K23 HL146942/HL/NHLBI NIH HHS/United States